MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the treatment of severe burns, chronic and other hard-to-heal wounds, and connective tissue disorders. Its lead product candidate is EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.